论文部分内容阅读
Objective:To determine the clinical serum levels of carcinoembryonic antigen(CEA) and carbohydrate antigen 19-9(CA19-9),individually and in combination,for the diagnosis of 50 healthy subjects and 150 cases of esophageal,gastric,and colon cancers.Methods:The sensitivities of the two markers were compared individually and in combination,with specificity set at 100%.Receiver operating characteristic(ROC) curves were plotted.Results:Serum CEA levels were significantly higher in cancer patients than in the control group.The sensitivity of CEA was determined:in esophageal cancer,sensitivity=28%,negative predictive value(NPV)=61.72%,and AUC=0.742(SE=0.05),with a significance level of P<0.0001;in gastric cancer,sensitivity=30%,NPV=58.82%,and AUC=0.734(SE=0.05),with a significance level of P<0.0001;in colon cancer,sensitivity=74%,NPV=79.36%,and AUC=0.856(SE=0.04),with a significance level of P<0.0001.The sensitivity of CA19-9 was also evaluated:in esophageal cancer,sensitivity=18%,NPV=54.94%,and AUC=0.573(SE=0.05),with a significance level of P=0.2054.In gastric cancer,sensitivity=42%,NPV=63.29%,and AUC=0.679(SE=0.05),with a significance level of P<0.0011.In colon cancer,sensitivity=26%,NPV=57.47%,and AUC=0.580(SE=0.05),with a significance level of P=0.1670.The following were the sensitivities of CEA/CA19-9 combined:in esophageal cancer,sensitivity=42%,NPV=63.29%,SE=0.078(95% CI:0.0159-0.322);gastric cancer,sensitivity=58%,NPV=70.42%,SE=0.072(95% CI:-0.0866-0.198);and colon cancer,sensitivity=72%,NPV=78.12%,SE=0.070(95% CI:0.137-0.415).Conclusion:CEA exhibited the highest sensitivity for colon cancer,and CA19-9 exhibited the highest sensitivity for gastric cancer.Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.
Objective: To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. Methods: The sensitivities of the two markers were individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Results: Serum CEA levels were significantly higher in cancer patients than in the control group. sensitivity of CEA was determined in esophageal cancer with sensitivity = 28%, negative predictive value (NPV) = 61.72%, and AUC = 0.742 (SE = 0.05) with a significance level of P <0.0001; With a significance level of P <0.0001; in colon cancer, sensitivity = 74%, NPV = 79.36%, and AUC = 0.856 (SE = 0.04) , with a significance level of P <0.0001. sensitivity of CA19-9 was also evaluated in esophageal cancer, sensitivity = 18%, NPV = 54.94%, a with a significance level of P = 0.2054. In gastric cancer, sensitivity = 42%, NPV = 63.29% and AUC = 0.679 (SE = 0.05) with a significance level of P < With a significance level of P = 0.1670. The following were the sensitivities of CEA / CA19-9 combined: in esophageal (95% CI: 0.0159-0.322); gastric cancer, sensitivity = 58%, NPV = 70.42%, SE = 0.072 (95% CI: -0.0866-0.198 ); and colon cancer, sensitivity = 72%, NPV = 78.12%, SE = 0.070 (95% CI: 0.137-0.415) .Conclusion: CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer.Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.